Avoidance of surgery for head and neck infantile myofibromatosis using imatinib monotherapy. Issue 2 (9th February 2022)

• Record Type: Journal Article
• Authors: Pattisapu, Prasanth; Wenger, Tara L.; Dahl, John P.; Bly, Randall A.; Bonilla‐Velez, Juliana; Wu, Natalie; Hall, Anurekha; Rudzinski, Erin R.; Perkins, Jonathan A.
• Is Part Of: Clinical case reports. Volume 10:Issue 2(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-02-09
• Subjects: imatinib -- Infantile myofibromatosis -- PDGFRB -- precision medicine; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.5382
• Languages: English
• ISSNs: 2050-0904

Abstract

Abstract: Describe a novel use for a kinase inhibitor, imatinib, in young children with a known activated somatic mutation in PDGFR‐beta. Two patients with infantile myofibromatosis treated with imatinib. Case description of evaluation, diagnosis and treatment decisions for infantile myfibromatosis of the head and neck. Description of medical therapy for infantile myofibromatosis in these patients. For function threatening myofibromas of a known genotype, in infants, targeted medical therapy is a treatment option. Abstract : Tumors associated with infantile myofibromatosis are potentially sensitive to monotherapy with tyrosine kinase inhibitors like imatinib. Such treatment may avoid surgery or chemotherapy, but further study is needed, especially on treatment duration.